GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: hMN-14-SN-38 | hMN-14-SN-38 ADC | IMMU 130 | IMMU-130
                                 Compound class: 
                                                            Antibody
                                 
                                    
                                        Comment: Labetuzumab govitecan (research code IMMU-130) is an antibody-drug conjugate (ADC) in which the anti-CEACAM5 antibody labetuzumab, is covalently bound to SN-38, the active metabolite of the topoisomerase inhibitor irinotecan (as exemplified in patents [2] and [1]).
                                    
                                 | 
| Classification  | |
| Compound class | Antibody | 
| International Nonproprietary Names  | |
| INN number | INN | 
| 10096 | labetuzumab govitecan | 
| Synonyms  | 
| hMN-14-SN-38 | hMN-14-SN-38 ADC | IMMU 130 | IMMU-130 | 
| Database Links  | |
| GtoPdb PubChem SID | 249565932 | 
| Search PubMed clinical trials | labetuzumab govitecan | 
| Search PubMed titles | labetuzumab govitecan | 
| Search PubMed titles/abstracts | labetuzumab govitecan |